CAM
TBIO

Cormorant Asset Management’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Cormorant Asset Management’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-454,549
Closed -$4.63M – 79
2019
Q1 		$4.63M Sell
454,549
-1
-0% -$8 0.31% 51
2018
Q4 		$3.41M Hold
454,550
– – 0.28% 58
2018
Q3 		$4.55M Hold
454,550
– – 0.3% 51
2018
Q2 		$5.75M Buy
+454,550
New +$5.49M 0.43% 46

Other funds holding TBIO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Cormorant Asset Management's TBIO Position: Q2 2019 in Review

Cormorant Asset Management sold out of Translate Bio, Inc. Common Stock (TBIO) in Q2 2019, closing a stake of 454,549 shares — an estimated $4.63M sold.

Cormorant Asset Management first reported a position in TBIO in Q2 2018 and held it in 4 quarters. The position peaked at $5.75M in Q2 2018. 60 funds tracked by Wall St. Rank hold TBIO as of Q2 2019.

  • Cormorant Asset Management reported no remaining Translate Bio, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Cormorant Asset Management sold 454,549 Translate Bio, Inc. Common Stock shares in Q2 2019, an estimated $4.63M.
  • Cormorant Asset Management first reported a position in Translate Bio, Inc. Common Stock in Q2 2018 and held it in 4 quarters.
  • Cormorant Asset Management's Translate Bio, Inc. Common Stock position peaked at $5.75M in Q2 2018.
  • 60 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q2 2019.

Based on Cormorant Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.